Hiv Replication

CD4 binding initiates recognition of a susceptible host cell, while interaction with a chemokine coreceptor enables the membrane-fusion step that allows the virus to enter. This two-part requirement helps determine which cells can support infection and identifies distinct points where entry-blocking antiretroviral drugs can interfere with replication before viral genetic material is copied.

Reverse transcriptase first converts the viral RNA genome into DNA inside the infected cell. Integrase then inserts that viral DNA into the host genome, creating a genetic template that host cellular machinery can use to produce viral RNA and proteins. Because these enzymes act at successive stages, blocking either one prevents the later stages from proceeding normally.

Protease acts after new viral particles have assembled and budded from the host cell. It cleaves viral protein products into functional components, allowing the particle to mature into an infectious form. Without this processing step, particle release can still occur, but the resulting virus cannot complete maturation properly, making protease a distinct antiretroviral target.

Researchers can organize the process as a linked sequence: cellular attachment, coreceptor-dependent fusion, RNA-to-DNA conversion, genome integration, production of viral RNA and proteins, particle assembly, budding, and protease-driven maturation. Examining the stages in this order helps identify where a replication defect occurs and connects each defect with a specific viral enzyme, host process, or drug target.

Antiretroviral therapy can interfere with several stages, including entry, reverse transcription, integration, and protease activity. These targets represent different dependencies of the viral life cycle rather than repeated effects on one step. Mapping a drug to its stage of action helps explain how treatment interrupts production of new infectious virus and why replication is best understood as a multistep process.

Replication links molecular events inside an infected cell to broader effects on the immune system. The virus uses host machinery to produce additional viral components, while successful assembly and maturation generate new infectious particles capable of continuing the cycle. Studying this relationship helps biology researchers connect viral life-cycle stages with HIV-associated loss of immune-cell function and therapeutic intervention.